Gene · 27036
Papers1,589
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,589
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Innate and adaptive immune features associated with immune-related adverse events. | J Immunother Cancer | 2025 | 40930749 | PubTator, text mining | PubMed |
| Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8+ T cell exhaustion-suppressed antitumor immunity. | Sci Adv | 2025 | 40815657 | PubTator, text mining | PubMed |
| Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation and migration of bladder cancer cells mediated by CENPA. | Sci Rep | 2025 | 40804263 | PubTator, text mining | PubMed |
| Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression. | Front Immunol | 2025 | 40761794 | PubTator, text mining | PubMed |
| CD8 T Cell Hyperfunction and Reduced Tumour Control in Murine Models of Advanced Liver Disease. | Eur J Immunol | 2025 | 40760842 | PubTator, text mining | PubMed |
| GD2-mediated impairment of macrophage phagocytosis drives pulmonary metastasis in osteosarcoma. | Theranostics | 2025 | 40756348 | PubTator, text mining | PubMed |
| The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohorts. | EBioMedicine | 2025 | 40737757 | PubTator, text mining | PubMed |
| An ultrasensitive and modular platform to detect Siglec ligands and control immune cell function. | bioRxiv | 2025 | 40661511 | PubTator, text mining | PubMed |
| Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway. | Cells | 2025 | 40643462 | PubTator, text mining | PubMed |
| Aging modulates the immunosuppressive, polarizing and metabolic functions of blood-derived myeloid-derived suppressor cells (MDSCs). | Immun Ageing | 2025 | 40629365 | PubTator, text mining | PubMed |
| Interleukin-32-expressing CD4+ T cells are a potentially pathogenic subset in systemic sclerosis with interstitial lung disease. | Respir Investig | 2025 | 40617174 | PubTator, text mining | PubMed |
| Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients. | Front Immunol | 2025 | 40547037 | PubTator, text mining | PubMed |
| Chemical and Enzymatic Synthesis of DisialylGb5 and Other Sialosides for Glycan Array Assembly and Evaluation of Siglec-Mediated Immune Checkpoint Inhibition. | Molecules | 2025 | 40509155 | PubTator, text mining | PubMed |
| Molecular Basis of Siglec‑7 Recognition by Neisseria meningitidis Serogroup Y CPS: Implications for Immune Evasion. | JACS Au | 2025 | 40443894 | PubTator, text mining | PubMed |
| Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR. | Front Immunol | 2025 | 40433387 | PubTator, text mining | PubMed |
| Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment. | Front Immunol | 2025 | 40375999 | PubTator, text mining | PubMed |
| The Human Bone Marrow May Offer an IL-15-Dependent Survival Niche for EOMES+ Tr1-Like Cells. | Eur J Immunol | 2025 | 40375822 | PubTator, text mining | PubMed |
| Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations. | Front Immunol | 2025 | 40313947 | PubTator, text mining | PubMed |
| Synthesis of 4-azido sialic acid for testing against Siglec-7 and in metabolic oligosaccharide engineering. | RSC Chem Biol | 2025 | 40309065 | PubTator, text mining | PubMed |
| Insights into Siglec-7 Binding to Gangliosides: NMR Protein Assignment and the Impact of Ligand Flexibility. | Adv Sci (Weinh) | 2025 | 40285643 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27036/papers?page=3